Prof. Claude Wischik - Co-Founder, Chairman and Chief Executive

Professor Wischik is board-certified in psychiatry, professor of Old Age Psychiatry at the University of Aberdeen, Scotland. A pioneer in Tau research, he discovered the tau protein compositional structure of the Alzheimer’s tangles and established that it was possible to dissolve tangles with pharmaceutically viable compounds that act as Tau Aggregation Inhibitors.

Mr. Timothy Earle - Chief Operating Officer / Chief Business Officer

Mr. Earle has 30 years’ involvement in the commercial aspects of innovative drug development having previously served as Commercial Director of the Proxima Concepts group of companies, Group Finance Director of BRX Research & Development Ltd. and Principal Consultant at PA Consulting Group. He holds a BA (Hons) in Business Studies from the University of Hertfordshire and an MBA from The Wharton School, University of Pennsylvania.

Dr Jiri Hardlund - Chief Medical Officer

Dr Harlund has 25 years’ experience of clinical development having worked for Bayer as VP of clinical development, planning and executing the Phase I-III clinical development of all Bayer’s drug candidates in Japan. His primary responsibility at TauRx is for the management of the entire clinical development programme of LMTX™.

Dr Charles Harrington - Chief Scientific Officer

Dr Harrington has extensive research experience in the field of neurodegenerative diseases and is author of more than 50 publications and co-inventor in 12 patent applications in this area. He has collaborated with Professor Wischik for over 20 years, developing assays for screening agents having the potential to prevent the tau pathology that is the hallmark of Alzheimer’s disease.

Prof. John Storey - Head of Technical

Professor Storey holds the Chair of Pharmaceutical Industrial Chemistry at University of Aberdeen; co-inventor in 10 patent applications, he and his team have synthesized TauRx’s portfolio of drug candidates and are responsible for their chemical scale-up, analysis, encapsulation and formulation. He also manages the TauRx GLP test facility, situated at the University of Aberdeen, which is the only University-based facility in the UK that is both GLP and GCP compliant, and is a co-inventor of 10 patents pending with TauRx.

Hwang Hong Wei - Finance Director

Mr Hwang is a member of the Institute of Certified Public Accountants of Singapore and joined TauRx Pharmaceuticals Ltd in March 2010. Previously, he was Finance Director of LexisNexis Asia and held senior positions in finance in the IT and financial industry. He holds a Bachelor of Accountancy (Honours) from the National University of Singapore and a Master of Science in CFO Leadership from the Singapore Management University.

Lawrence Wong Kin Meng - Company Secretary and Legal Advisor

Mr. Wong was called to the English Bar in 1983 as a Barrister and admitted to the Singapore Bar as an Advocate & Solicitor in 1984. He worked in several large and medium-sized law firms in Singapore, before establishing his own law firm in July 2000. Concurrently with his law practice, he holds appointments as a Notary Public and Commissioner for Oaths.